ITRM
insider transactionsIterum Therapeutics plc — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
+21.0K
21.0K buy · 0 sell
Net value · 365d
$13.0K
$13.0K in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
2
21.0K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Buy·P
Director
$2.2K
6.0K sh · $0.37
Own +3%
-
Buy·P
Director
$10.8K
15.0K sh · $0.72
Own +7%
-
Grant·A
Chief Commercial Officer
$0
200.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Nov 18, 2025 | Dunne Michael W. | Buy P | 6.0K | $2.2K |
| Aug 8, 2025 | Dunne Michael W. | Buy P | 15.0K | $10.8K |
| Jul 1, 2025 | Coyne Christine | Grant A | 200.0K | $0 |
About ITRM insider trading
This page tracks insider transactions for Iterum Therapeutics plc (ITRM) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.